An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients
- Registration Number
- NCT07057856
- Lead Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
- Brief Summary
From January 2018 to May 2025, diagnosed CD patients and gender- and age-matched normal controls were collected from Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. Our study aimed to explore the associations of interleukin 12 receptor subunit beta 1 (IL-12RB1) gene polymorphisms with the risk and clinicopathological characteristics of Crohn's disease (CD), and to analyze the effects of IL-12RB1 gene variations on the clinical response of ustekinumab (UST) treatment in CD patients at week 8.
- Detailed Description
From January 2018 to May 2025, diagnosed CD patients and gender- and age-matched normal controls were collected from Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. Genotypes of IL-12RB1 were examined by multiplex polymerase chain reaction-ligase detection reaction technique. Unconditional logistic regression analysis was employed to analyze the distribution differences of IL-12RB1 gene polymorphisms between CD group and normal control group, as well as their influences on the clinicopathological characteristics and 8-week clinical response to UST treatment of CD patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 866
- diagnosed CD based on comprehensive clinical, colonoscopy, histopathological, laboratory, and radiographic examination results
- rheumatoid arthritis, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis, tumors, etc.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description CD patients Ustekinumab (UST) Some CD patients received UST treatment and the first sufficient dose of UST (6mg/kg) was administered intravenously.
- Primary Outcome Measures
Name Time Method Genotypes of IL-12RB1 Baseline multiplex polymerase chain reaction-ligase detection reaction technique
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
the Second Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, Zhejiang, China
the Second Affiliated Hospital of Wenzhou Medical University🇨🇳Wenzhou, Zhejiang, China